Pharmacokinetics of UH and LMWH are similar with respect to antithrombin activity

Thrombosis Research

Volumn 115, Issue 1-2, 2005, Pages 45-51

  Morris, Timothy A ^a   Jacobson, Alan ^b   Marsh, James J ^a   Lane, James R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Anticoagulation; Heparin; Low molecular weight heparin; Pharmacokinetics

Indexed keywords

DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; TINZAPARIN; WARFARIN;

ADULT; AGED; ANTICOAGULATION; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE;

AGED; AREA UNDER CURVE; BODY WEIGHT; DALTEPARIN; ENOXAPARIN; FEMALE; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; MIDDLE AGED; REGRESSION ANALYSIS; THROMBIN;

EID: 9644265348     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2004.07.010     Document Type: Article

References (33)

1. T.M. Hyers, G. Agnelli, R.D. Hull, T.A. Morris, M. Samama, and V. Tapson Antithrombotic therapy for venous thromboembolic disease Chest 119 1 Suppl 2001 176S 193S [JID-0231335]
2. P. Prandoni, P. Bagatella, E. Bernardi, B. Girolami, L. Rossi, and L. Scarano Use of an algorithm for administering subcutaneous heparin in the treatment of deep venous thrombosis Ann. Intern. Medicin. 129 4 1998 299 302
3. J. Hirsh, and M.N. Levine Low molecular weight heparin Blood 79 1 1992 1 17
4. T.A. Morris, J.J. Marsh, R. Konopka, C.A. Pedersen, and PG. Chiles Anti-thrombotic efficacies of enoxaparin, dalteparin, and unfractionated heparin in venous thromboembolism Thromb. Res. 100 3 2000 185 194 [JID-0326377]
5. D. Carrie, C. Caranobe, and B. Boneu A comparison of the antithrombotic effects of heparin and of low molecular weight heparins with increasing antifactor xa/antifactor iia ratio in the rabbit Br. J. Hematol. 83 1993 622 626
6. A. Leizorovicz, L. Bara, M.M. Samama, and M.C. Haugh Factor xa inhibition: correlation between the plasma levels of anti-xa activity and occurrence of thrombosis and haemorrhage Haemostasis 23 Suppl 1 1993 89 98
7. A.V. Bendetowicz, S. Beguin, H. Caplain, and H.C. Hemker Pharmacokinetics and pharmacodynamics of a low molecular weight heparin (enoxaparin) after subcutaneous injection, comparison with unfractionated heparin-a three way cross over study in human volunteers Thromb. Haemost. 71 1994 305 313
8. R.R. Sokal F.J. Rohlf Biometry: the principles and practice of statistics in biological research 3rd ed. 1995 Freeman New York 148
9. E. Lindhoff-Last, G. Mosch, and H.K. Breddin Treatment doses of different low molecular weight heparins and unfractionated heparins differ in their anticoagulating effects in respect to aptt, heptest, anti-iia- and anti-xa-activity Lab. Med. 16 1992 174 177
10. J. Harenberg, G. Stehle, M. Blauth, K. Huck, K. Mall, and D.L. Heene Dosage, anticoagulant, and antithrombotic effects of heparin and low-molecular-weight heparin in the treatment of deep vein thrombosis Semin. Thromb. Hemost. 23 1 1997 83 90
11. S. Beguin, D. Welzel, R. Al Dieri, and H.C. Hemker Conjectures and refutations on the mode of action of heparins. The limited importance of anti-factor xa activity as a pharmaceutical mechanism and a yardstick for therapy Haemostasis 29 2-3 1999 170 178 [JID-0371574]
12. R.T. Barrow, E.T. Parker, S. Krishnaswamy, and P. Lollar Inhibition by heparin of the human blood coagulation intrinsic pathway factor x activator J. Biol. Chem. 269 43 1994 26796 26800
13. S. Anand, J.S. Ginsberg, C. Kearon, M. Gent, and J. Hirsh The relation between the activated partial thromboplastin time response and recurrence in patients with venous thrombosis treated with continuous intravenous heparin Arch. Intern. Med. 156 15 1996 1677 1681
14. S.S. Anand, S. Bates, J.S. Ginsberg, M. Levine, H. Buller, and M. Prins Recurrent venous thrombosis and heparin therapy: an evaluation of the importance of early activated partial thromboplastin times Arch. Intern. Med. 159 17 1999 2029 2032
15. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. The Columbus Investigators N. Engl. J. Med. 337 10 1997 657 662
16. G. Belcaro, A.N. Nicolaides, M.R. Cesarone, G. Laurora, L. Incandela, and A. Barsotti Comparison of low-molecular-weight heparin, administered primarily at home, with unfractionated heparin, administered in hospital, and subcutaneous heparin, administered at home for deep-vein thrombosis Angiology 50 1999 781 787
17. J.N. Fiessinger, M. Lopez-Fernandez, E. Gatterer, S. Granqvist, A. Kher, and C.G. Olsson Once-daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis Thromb. Haemost. 76 2 1996 195 199
18. C.M. Kirchmaier, H. Wolf, H. Scheafer, B. Ehlers, and H.K. Breddin Efficacy of a low molecular weight heparin administered intravenously or subcutaneously in comparison with intravenous unfractionated heparin in the treatment of deep venous thrombosis. Certoparin-Study Group Int. Angiol. 17 3 1998 135 145
19. M.M. Koopman, P. Prandoni, F. Piovella, P.A. Ockelford, D.P. Brandjes, and J. van der Meer Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group [see comments] [published erratum appears in N. Engl. J. Med. 1997 Oct 23;337(17):1251] N. Engl. J. Med. 334 11 1996 682 687
20. M. Levine, M. Gent, J. Hirsh, J. Leclerc, D. Anderson, and J. Weitz A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis [see comments] N. Engl. J. Med. 334 11 1996 677 681
21. P. Lindmarker, M. Holmstreom, S. Granqvist, H. Johnsson, and D. Lockner Comparison of once-daily subcutaneous fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis Thromb. Haemost. 72 2 1994 186 190
22. K. Luomanmeaki, S. Grankvist, C. Hallert, I. Jauro, K. Ketola, and H.C. Kim A multicentre comparison of once-daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis J. Int. Med. 240 2 1996 85 92
23. G. Merli, T.E. Spiro, C.G. Olsson, U. Abildgaard, B.L. Davidson, and A. Eldor Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease Ann. Intern. Med. 134 3 2001 191 202
24. G. Meyer, F. Brenot, G. Pacouret, G. Simonneau, J. Gillet, and B. Charbonnier Subcutaneous low-molecular-weight heparin fragmin versus intravenous unfractionated heparin in the treatment of acute non massive pulmonary embolism: an open randomized pilot study Thromb. Haemost. 74 6 1995 1432 1435
25. P. Prandoni, A.W. Lensing, H.R. Buller, M. Carta, A. Cogo, and M. Vigo Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis Lancet 339 8791 1992 441 445
26. G. Simonneau, H. Sors, B. Charbonnier, Y. Page, J.P. Laaban, and R. Azarian A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The Thesee Study Group. Tinzaparine ou heparine standard: evaluations dans l'embolie pulmonaire N. Engl. J. Med. 337 10 1997 663 669
27. R.D. Hull, G.E. Raskob, G.F. Pineo, D. Green, A.A. Trowbridge, and C.G. Elliott Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis [see comments] N. Engl. J. Med. 326 15 1992 975 982
28. G. Andersson, B. Fagrell, K. Holmgren, H. Johnsson, B. Ljungberg, and E. Nilsson Subcutaneous administration of heparin. A randomised comparison with intravenous administration of heparin to patients with deep-vein thrombosis Thromb. Res. 27 1982 631 639
29. H.W. de Valk, J.D. Banga, J.W. Wester, C.B. Brouwer, M.W. van Hessen, and O.J. Meuwissen Comparing subcutaneous danaparoid with intravenous unfractionated heparin for the treatment of venous thromboembolism. A randomized controlled trial [see comments] Ann. Intern. Med. 123 1 1995 1 9
30. D.J. Doyle, A.G. Turpie, J. Hirsh, C. Best, D. Kinch, and M.N. Levine Adjusted subcutaneous heparin or continuous intravenous heparin in patients with acute deep vein thrombosis. A randomized trial Ann. Intern. Med. 107 1987 441 445
31. R. Hull, T. Delmore, C. Carter, J. Hirsh, E. Genton, and M. Gent Adjusted dose subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis N. Engl. J. Med. 306 4 1982 189 194
32. L. Briant, C. Caranobe, S. Saivin, P. Sie, B. Bayrou, and G. Houin Unfractionated heparin and cy 216: pharmacokinetics and bioavailabilities of the antifactor xa and iia effects after intravenous and subcutaneous injection in the rabbit Thromb. Haemost. 61 1989 348 353
33. A.M. Frydman, L. Bara, Y. Le Roux, M. Woler, F. Chauliac, and M.M. Samama The antithrombotic activity and pharmacokinetics of enoxaparine, a low molecular weight heparin, in humans given single subcutaneous doses of 20 to 80 mg J. Clin. Pharmacol. 28 1988 609 618